In fiscal year 2013, we continued to evaluate oncology patients at risk for the development of cutaneous toxicities associated with molecularly targeted therapies. These evaluations included baseline evaluations prior to initiation of treatment and follow-up visits to monitor and treat these skin toxicities. We work with oncology colleagues to optimally design treatment protocols to evaluate for cutaneous toxicities and to inform the research community of potentially newly described skin toxicities and methods for management of these adverse effects to optimize continued antineoplastic treatment of oncology patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010940-06
Application #
8763275
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2013
Total Cost
$32,772
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Azad, Nilofer S; Aragon-Ching, Jeanny B; Dahut, William L et al. (2009) Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 15:1411-6
Lacouture, Mario E; Wu, Shenhong; Robert, Caroline et al. (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13:1001-11
Kong, Heidi H; Sibaud, Vincent; Chanco Turner, Maria L et al. (2008) Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol 144:820-2